A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.

Article Details

Citation
Copy to clipboard

Bongomin F, Oladele RO, Gago S, Moore CB, Richardson MD

A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.

Mycoses. 2018 May;61(5):290-297. doi: 10.1111/myc.12747. Epub 2018 Feb 14.

PubMed ID
29377368 [ View in PubMed
]
Abstract

Fluconazole is the most commonly used antifungal agent for both the treatment of cryptococcal meningitis, and for prophylaxis against the disease. However, its prolonged use has the potential to exert selection pressure in favour of fluconazole-resistant strains. We evaluated the prevalence of fluconazole resistance in Cryptococcus spp. clinical isolates in 29 studies from 1988 to May 2017 included in EMBASE and MEDLINE databases. A total of 4995 Cryptococcus isolates from 3210 patients constituted this study; 248 (5.0%) of the isolates from relapsed episodes of cryptococcosis were included in this analysis. Eleven (38%) of the studies used minimum inhibitory concentrations (MICs) breakpoints of >/=64 mug/mL to define fluconazole resistance, 6 (21%) used >/=32 mug/mL, 11 (38%) used >/=16 mug/mL and 1 (3%) used

DrugBank Data that Cites this Article

Drugs